Aflibercept Off-Target Effects in Diabetic Macular Edema: An In Silico Modeling Approach
Intravitreal aflibercept injection (IAI) is a treatment for diabetic macular edema (DME), but its mechanism of action (MoA) has not been completely elucidated. Here, we aimed to explore IAI’s MoA and its multi-target nature in DME pathophysiology with an in silico (computer simulation) disease model...
Main Authors: | Morgane Blanot, Ricardo Pedro Casaroli-Marano, Jordi Mondéjar-Medrano, Thaïs Sallén, Esther Ramírez, Cristina Segú-Vergés, Laura Artigas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/25/7/3621 |
Similar Items
-
Aflibercept monotherapy or bevacizumab first for diabetic macular edema
by: Avner Hostovsky, et al.
Published: (2024-01-01) -
Clinical Application of Intravitreal Aflibercept Injection for Diabetic Macular Edema Comparing Two Loading Regimens
by: Yoo-Ri Chung, et al.
Published: (2023-03-01) -
Ranibizumab versus aflibercept for macular edema secondary to nonischemic central retinal vein occlusion in young adult patients
by: Ahmed A Amer, et al.
Published: (2022-01-01) -
Efficacy of Modified Treat-and-Extend Aflibercept Regimen for Macular Edema Due to Branch Retinal Vein Occlusion: 1-Year Prospective Study
by: Yusuke Arai, et al.
Published: (2020-07-01) -
Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
by: Siamak Moradian, et al.
Published: (2023-04-01)